Topic: Bladder Cancer

The Gold Standard for Bladder Cancer Detection

Neal D. Shore, MD, discusses the benefits of using blue light cystoscopy (BLC) in adjunct with white light cystoscopy (WLC) in the diagnosis and treatment of bladder cancers. He then reviews the body of evidence evaluating the accuracy of BLC in detecting significant tumors and briefly compares BLC and narrow band imaging.

Read More

BCG Maintenance Should Be Less Intense

Michael S. Cookson, MD, MMHC, suggests that the primary evidence does not provide convincing evidence in favor of 3 years of bacillus Calmette-Guérin (BCG) maintenance for non-muscle-invasive bladder cancer (NMIBC). He also notes that long-term BCG often leads to toxicities, contributing to low patient compliance.

Read More

T1 Bladder Cancer

Seth P. Lerner, MD, provides an overview of T1 bladder cancer staging and treatment, emphasizing the importance of re-TUR. He then discusses when to offer radical cystectomy or BCG, and options for patients who have failed BCG.

Read More

Checkpoint Inhibitors for NMIBC

Daniel P. Petrylak, MD, provides an overview of immunotherapy treatment options for non-muscle invasive bladder cancer (NMIBC) including BCG, intravesical therapies, and checkpoint inhibitors. He also discusses clinical trials investigating alternative immunotherapy options for NMIBC other than BCG.

Read More

Can MR Imaging Help Triage Bladder Cancer Patients?

John C. Chang, MD, PhD, examines the potential of MRI for staging bladder cancer, emphasizing MRI’s facility in differentiating between muscle invasive and non-muscle invasive bladder cancer (NMIBC). He also acknowledges that MRI scanning can lead to overstaging, and that CT can be effective for detecting higher stages of bladder cancer.

Read More

Urinary Markers in NMIBC: What’s New?

Sanjay G. Patel, MD, defines challenges in the detection and surveillance of bladder cancer when using FDA-approved biomarkers. He then evaluates newer DNA methylation- , DNA mutations- , and mRNA-based biomarkers and their ability to account for the limitations of traditional markers.

Read More

BCG Unresponsive Disease

Sanjay G. Patel, MD, discusses various definitions of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). He also outlines treatment options available for these patients and the clinical trials evaluating each approach.

Read More

Join the GRU Community

- Why Join? -